Sugi Predict

Sugi Predict / Compounds / SCHEMBL902030

SCHEMBL902030

SCHEMBL902030

OCc1ccc(F)cc1B(O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.34
▸ AGXT P21549 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ LIPE Q05469 1/20 0.34
▸ ENPP2 Q13822 2/20 0.33
▸ ORAI1 Q96D31 1/20 0.33
▸ ORAI2 Q96SN7 1/20 0.33
▸ ORAI3 Q9BRQ5 1/20 0.33
▸ TRPV6 Q9H1D0 1/20 0.33
▸ CA3 P07451 1/20 0.32
▸ CA6 P23280 1/20 0.32
▸ CA5A P35218 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ CA14 Q9ULX7 1/20 0.32
▸ CA5B Q9Y2D0 1/20 0.32
▸ ACHE P22303 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519062 0.83 CXCR2 (0.39) SMN1; SMN2ENPP2ORAI1ORAI2ORAI3
SCHEMBL456808 0.83 CXCR2 (0.39) SMN1; SMN2ENPP2ORAI1ORAI2ORAI3
SCHEMBL29953073 0.82 MPO (0.41) IDO1AGXTKDM4ESMN1; SMN2LIPE
SCHEMBL9938729 0.82 MPO (0.41) IDO1AGXTKDM4ESMN1; SMN2LIPE
Hydrochloric Acid SCHEMBL3761659 0.80 MPO (0.40) IDO1AGXTKDM4ELIPEMAOB
Hydrochloric Acid SCHEMBL29951319 0.80 MPO (0.40) IDO1AGXTKDM4ELIPEMAOB
SCHEMBL16576644 0.79 RIPK1 (0.35) IDO1AGXTKDM4ESMN1; SMN2LIPE
SCHEMBL28983761 0.79 IDO1 (0.39) IDO1AGXTSMN1; SMN2LIPEENPP2
SCHEMBL30396772 0.79 IDO1 (0.39) IDO1AGXTSMN1; SMN2LIPEENPP2
SCHEMBL3791071 0.77 ENPP2 (0.45) KDM4EENPP2CA3CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3805236-B1 FLUORESCENT COMPOUND AND FLUORESCENT LABELED BIOLOGICAL SUBSTANCE USING THE SAME FUJIFILM CORP (JP) 2026-05-06 — — EP disclosed
US-11988667-B2 Fluorescent compound and fluorescent labeled biological substance using the same FUJIFILM CORPORATION (JP) 2024-05-21 — — US disclosed
EP-3774775-B1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2023-10-11 — — EP disclosed
US-11505543-B2 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2022-11-22 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
EP-3805236-A1 FLUORESCENT COMPOUND, AND FLUORESCENTLY-LABELED BIOLOGICAL SUBSTANCE USING SAME FUJIFILM Corporation (JP) 2021-04-14 — — EP disclosed
US-20210088526-A1 FLUORESCENT COMPOUND AND FLUORESCENT LABELED BIOLOGICAL SUBSTANCE USING THE SAME FUJIFILM CORPORATION (JP) 2021-03-25 — — US disclosed
EP-3774775-A1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-02-17 — — EP disclosed
US-20210024503-A1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-01-28 — — US disclosed
WO-2019198024-A1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2019-10-17 — — WO disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 — — US disclosed
US-8791129-B2 Phenylquinazoline derivatives MERCK PATENT GMBH (DE) 2014-07-29 — — US disclosed
US-8791129-B2 Phenylquinazoline derivatives MERCK PATENT GMBH (DE) 2014-07-29 — — US disclosed
US-8791129-B2 Phenylquinazoline derivatives MERCK PATENT GMBH (DE) 2014-07-29 — — US disclosed
EP-2621919-A1 PHENYLQUINAZOLINE DERIVATIVES Merck Patent GmbH (DE) 2013-08-07 — — EP disclosed
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-07-11 — — US disclosed
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-07-11 — — US disclosed
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-07-11 — — US disclosed
WO-2012041435-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-04-05 — — WO disclosed
WO-2012041435-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024503-A1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, CCNI, IRF3 IDO1 501/4885AGXT 2765/4885KDM4E 484/4885
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 IDO1 2763/4885AGXT 4780/4885KDM4E 2769/4885
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES HSP90B1, HSP90AB1, HSP90AA1 IDO1 3550/4885AGXT 2569/4885KDM4E 3029/4885
US-11505543-B2 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication EIF2AK2, CCNI, IRF3 IDO1 501/4885AGXT 2765/4885KDM4E 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.